Cambrex Corporation, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), is investing $9 million to expand large-scale manufacturing capacity at its Karlskoga facility in Sweden. The investment includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational start up in Q4 201...